Month: September 2026

IRVINE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that it expects to present 11 scientific abstracts at the American Academy of Optometry (AAOpt) 2026 Annual Meeting, taking place Sept. 30–Oct. 3 in Anaheim, California.

The planned abstracts provide new insights into the patient burden, diagnosis and treatment of Demodex blepharitis (DB); real-world experiences and outcomes with XDEMVY^® (lotilaner ophthalmic solution) 0.25%; and the prevalence and clinical characteristics of ocular rosacea. Together, the findings are expected to add to a growing body of evidence intended to help eye care professionals better recognize and manage diseases that have historically been overlooked or undertreated.

“These 11 abstracts reflect the rapidly evolving understanding of Demodex blepharitis and ocular rosacea—two significant diseases that eye care professionals encounter every day. The findings deepen our understanding of each disease and the impact they can have on patients,” said Elizabeth Yeu, M.D., Chief Medical Officer of Tarsus.

Accepted abstracts include:

Real-World Longitudinal Study of Patients with Demodex Blepharitis and Soft Contact Lens Wear in the United States: Interim Data Analysis (Poster)
Date: Thursday, October 1, 2026, 4:30 – 6:30PM Pacific Daylight Time
Location: Anaheim Convention Center (ACC), Exhibit Hall
Presenter: Keith Wan, O.D.

Efficacy of Lotilaner 0.25% and Tea Tree Oil in Demodex Blepharitis: A Systematic Review and Meta-analysis (Poster)
Date: Thursday, October 1, 2026, 4:30 – 6:30PM Pacific Daylight Time
Location: ACC, Exhibit Hall
Presenter: Ian B. Gaddie, O.D.

Retrospective Chart Review of Demodex Blepharitis Prevalence Among Patients with Chalazia and/or Hordeola (Poster)
Date: Thursday, October 1, 2026, 4:30 – 6:30PM Pacific Daylight Time
Location: ACC, Exhibit Hall
Presenter: Andrew McLeod, O.D.

Prevalence of Ocular Rosacea in U.S. Eye Care Settings: A Multicenter Retrospective Chart Review (Poster)
Date: Thursday, October 1, 2026, 4:30 – 6:30PM Pacific Daylight Time
Location: ACC, Exhibit Hall
Presenter: Mile Brujic, O.D.

Assessment of Dry Eye Questionnaires for Demodex Blepharitis: Evidence from a Targeted Literature Review (Poster)
Date: Thursday, October 1, 2026, 4:30 – 6:30PM Pacific Daylight Time
Location: ACC, Exhibit Hall
Presenter: Walt Whitley, O.D.

Real-World Longitudinal Study of Patients with Demodex Blepharitis in the United States: 9-Month Follow-up Findings (Poster)
Date: Thursday, October 1, 2026, 4:30 – 6:30PM Pacific Daylight Time
Location: ACC, Exhibit Hall
Presenter: Vanesa Flores, O.D.

Real-World Clinician Re-treatment Practices and Decision Drivers with Lotilaner Ophthalmic Solution, 0.25% for Demodex Blepharitis (Poster)
Date: Thursday, October 1, 2026, 4:30 – 6:30PM Pacific Daylight Time
Location: ACC, Exhibit Hall
Presenter: Cecelia Koetting, O.D.

Real-World Patient-Reported Satisfaction and Factors Associated with Perceived Benefit of Lotilaner Ophthalmic Solution, 0.25% for Demodex Blepharitis (Poster)
Date: Thursday, October 1, 2026, 4:30 – 6:30PM Pacific Daylight Time
Location: ACC, Exhibit Hall
Presenter: Jessilin Quint, O.D.

Associations Between Demodex Infestation and Meibomian Gland Structure and Function: A Systematic Review (Poster)
Date: Thursday, October 1, 2026, 4:30 – 6:30PM Pacific Daylight Time
Location: ACC, Exhibit Hall
Presenter: Bridgitte Shen Lee, O.D.

Ocular Bacterial and Fungal Co-infestation in Demodex Infestation: A Systematic Review (Poster)
Date: Thursday, October 1, 2026, 4:30 – 6:30PM Pacific Daylight Time
Location: ACC, Exhibit Hall
Presenter: Pamela Theriot, O.D.

Assessment of Tea Tree-Based Management in Demodex Blepharitis: A Real-World Longitudinal Study (Paper)
Date: Friday, October 2, 2026, 4:00 – 4:15PM Pacific Daylight Time
Location: ACC, Room 255 C
Presenter: Selina McGee, O.D.

About Demodex Blepharitis
Blepharitis is a common lid margin disease that is characterized by eyelid margin inflammation, redness and ocular irritation. Demodex blepharitis is caused by an infestation of Demodex mites, the most common ectoparasites found on humans, and accounts for over two-thirds of all blepharitis cases. Demodex blepharitis may affect as many as 25 million Americans based on an extrapolation from the Titan study indicating 58% of patients presenting to U.S. eye care clinics have collarettes, a pathognomonic sign of Demodex mite infestation, and that at least 45 million people annually visit an eye care clinic. Demodex blepharitis can have a significant clinical burden and negative impact on patients’ daily lives.

About XDEMVY^®
XDEMVY (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03, is a novel prescription eye drop designed to treat Demodex blepharitis by targeting and eradicating the root cause of the disease – Demodex mite infestation. XDEMVY was evaluated in two pivotal trials involving over 800 patients with twice-daily dosing for six weeks. Both trials met the primary endpoint and all secondary endpoints, with statistical significance and no serious treatment-related adverse events. Most patients found the XDEMVY eye drop to be neutral to very comfortable. The most common ocular adverse reactions observed in the studies were instillation site stinging and burning which was reported in 10% of patients. Other ocular adverse reactions reported by less than 2% of patients were chalazion/hordeolum (stye) and punctate keratitis.

XDEMVY Indication and Important Safety Information

Indications and Usage
XDEMVY (lotilaner ophthalmic solution) 0.25% is indicated for the treatment of Demodex blepharitis.

Important Safety Information
Most common side effects: The most common side effect in clinical trials was stinging and burning in 10% of patients. Other side effects in less than 2% of patients were chalazion/hordeolum and punctate keratitis.

Handling the Container: Avoid allowing the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to minimize contamination of the solution. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

When to Seek Physician Advice: Immediately seek a physician’s advice concerning the continued use of XDEMVY if you develop an intercurrent ocular condition (e.g., trauma or infection), have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions.

Use with Contact Lenses: XDEMVY contains potassium sorbate, which may discolor soft contact lenses. Contact lenses should be removed prior to instillation of XDEMVY and may be reinserted 15 minutes following its administration.

To report SUSPECTED ADVERSE REACTIONS, contact Tarsus Pharmaceuticals at 1-888-421-4002 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For additional information please see Full Prescribing Information available at: www.xdemvy.com.

About Ocular Rosacea
Ocular rosacea is a prevalent, undertreated inflammatory disease affecting the eyes, eyelids and surrounding tissue. The condition may be associated with redness of the eyes and eyelids, prominent blood vessels, irritation and other ocular symptoms. Ocular rosacea is estimated to affect 15–18 million people in the United States, and there are currently no FDA-approved therapies specifically indicated for the disease.

About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. XDEMVY^® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of ocular rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease, both of which are in Phase 2, IRX-101 for potential use as an ocular antiseptic, and gildeuretinol for the potential treatment of Stargardt disease.

Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include statements regarding the timing, content, location, and presenters of scientific abstracts at an upcoming medical conference, our ability to continue to educate the market and generate data about Demodex blepharitis, the potential market size of Demodex blepharitis globally, and the quotations of Tarsus’ management. The words, without limitation, “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Further risks and uncertainties are detailed from time to time in the reports Tarsus files with the Securities and Exchange Commission, including Tarsus’ Form 10-K for the year ended December 31, 2025 filed with the SEC on February 23, 2026, and its most recent Form 10-Q filed with the SEC on August 6, 2026, copies of which are posted on its website and are available from Tarsus without charge. New risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements contained in this press release are based on the current expectations of Tarsus’ management team and speak only as of the date hereof, and Tarsus specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Media Contact:
Adrienne Kemp
Vice President, Corporate Communications
(949) 922-0801
akemp@tarsusrx.com 

Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com 

Plans To Commence World-First Phase 1b First-In-Human (FIH) Study of PRP Q1, 2027

MELBOURNE, Australia, Sept. 29, 2026 (GLOBE NEWSWIRE) — Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced an update on corporate progress and reported year-end financial results as of June 30, 2026 (Year end June 30).

CORPORATE HIGHLIGHTS

To commence a world-first Phase 1b FIH study of PRP in Q1, 2027

The multicenter, open-label study will enroll up to 50 patients with advanced solid tumors, including pancreatic, ovarian, and refractory prostate cancers, at trial centers across Australia. The two-part design, dose escalation (Part A) followed by dose expansion (Part B), is intended to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of PRP.

Several workstreams are advancing in parallel to support study start:

• Manufacturing: GMP manufacture of finished drug product is underway. A small-scale technology transfer run has been completed. Two scale-up runs are scheduled this month, with an engineering run planned for late October. Raw drug substance supply for the PRP formulation is secured after recent audit and vendor qualification processes were successfully completed.
• Bio-analytics: PK method validation has commenced. Development of an anti-drug antibody assay is underway, and in-use stability testing of the finished PRP formulation is scheduled.
• Regulatory and ethics: Supporting documentation for Human Research Ethics Committee (HREC) submission is in preparation, including the Investigator’s Brochure (IB), a briefing document drawn from the IB, and the clinical trial protocol. Documents will be provided to investigators at Australian trial sites for feasibility assessment ahead of the planned HREC submission in November 2026.

PRP will be administered as a weekly intravenous infusion on Days 1, 8, 15, and 22 of each 28-day cycle. Treatment may continue until a withdrawal criterion is met.

Compelling new preclinical and early translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma (PDAC)

In orthotopic and patient-derived xenograft (PDX) models of advanced PDAC, three-times-weekly intravenous PRP achieved:

• Greater than 90%, mean, tumor growth inhibition versus vehicle controls (p < 0.001).
• Marked reduction in metastatic burden in the liver and peritoneum.
• Significant remodeling of the tumor microenvironment, including decreased cancer-associated fibroblast activity, reduced fibrosis, and suppression of epithelial-mesenchymal transition (EMT) markers.
• Enhanced sensitivity of chemo-resistant PDAC cells to standard-of-care gemcitabine/nab-paclitaxel, supporting lower chemotherapy doses with improved efficacy.
• Median overall survival extension of more than 2.5-fold in treated animals compared with controls.

Results were built on previously reported >85% tumor growth inhibition data and peer-reviewed findings on PRP’s effects on PDAC fibroblasts. Limited prior compassionate-use experience with related proenzyme formulations has shown signals of prolonged survival in advanced solid-tumor patients with a favorable safety profile and no severe treatment-related adverse events.

Memorandum of Understanding (MOU) with Avance Clinical Pty Ltd

The MOU sets out the shared intent of Propanc and Avance to work together to support the clinical delivery of Propanc’s Phase 1b, FIH clinical study for PRP. Importantly, both parties intend to approach the collaboration in a spirit of openness, scientific rigor, and shared problem-solving with the goal of advancing PRP efficiently from FIH into Proof-of-Concept and, as data supports, later-phase development. Avance Clinical is a full-service Contract Research Organization (CRO) headquartered in Australia, with extensive operations across North America, Asia Pacific, New Zealand and Europe. With more than 30 years of experience leading early phase clinical trials, they leverage the unique advantages of the Australian market, including rapid ethics approval, and up to 43.5% off with the Australian R&D tax rebate, to provide biotech companies with an accelerated pathway to clinical success.

Contract and Development Manufacturing Organization (CDMO) for GMP manufacture of PRP

The Spanish based CDMO provides end-to-end services for preclinical and clinical projects, with extensive experience in biologics production (plasmid DNA and recombinant proteins) providing services of cell line generation, banking and characterization, analytical development, process development and batches production of both drug substances and drug products. Management are pleased to undertake this pivotal step for GMP production of PRP for the upcoming Phase 1 FIH clinical study.

Service Agreement with FyoniBio GmbH to Establish & Validate Pharmacokinetics Assay for Phase 1b FIH Study

Management has executed a service agreement with FyoniBio GmbH (formerly Glycotope, est. 2010), a German Contract Development Organization (CDO) based in Berlin for establishing and validating a liquid chromatography-mass spectrometry (LC-MS) based pharmacokinetics (PK) assay. The objective is to quantify the Company’s lead asset, PRP, consisting of two proenzymes trypsinogen and chymotrypsinogen, as well as their activated enzyme forms trypsin and chymotrypsin from human serum during the Phase 1b FIH study.

Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén & Granada, Spain

A multi-year Joint Research Collaboration Agreement has been established with the Universities of Jaén (UJA) and Granada (UGR), Spain. The collaboration involves the evaluation of a senescence-modulating (i.e., anti-aging) compound to mitigate senescence and to complete experiments to further support the claims of recently filed fibrosis and cancer related patent applications, requested by Propanc to UJA’s research group “Biological Technologies of The University of Jaén” and UGR’s Research Group, “Advanced Therapies: Differentiation, Regeneration and Cancer.”

FINANCIAL HIGHLIGHTS

Proceeds raised

In the 2025-26 financial year totaled $7.5 million, gross proceeds.

Closed an underwritten public offering

1,000,000 shares at $4.00 per share, raising gross proceeds of $4.0 million. Propanc’s common stock began trading on the Nasdaq Capital Market on August 15.

Entered into a private placement agreement for up to $100 million to accelerate clinical development

Received an initial $1,000,000 investment upon issuance of 100 shares of Series C, Convertible Preferred Stock. As of June 30, a further $3,000,000 investment was received upon exercise of 100 shares of Series C, Convertible Preferred Stock.

Commenced a share repurchase program authorizing the Company to repurchase up to $5.0 million of its common stock

The Company completed the first tranche of $500,000 within the first 30 days since of commencing its share repurchase program.

Year-end Financial Summary (Quarter Ended June 30, 2026)

• Total assets: $12.78 million
• Total liabilities reduced by $2.20 million
• Convertible notes reduced to $0 (from $538,000)
• Net cash from financing activities: $6.46 million
• Quarter-end cash: $832,006
• A further $2.0 million from the Series C facility received (post June 30)

The Company expects the financing facility to continually support planned R&D activities, including advancement of PRP and Rec-PRP.

Management Commentary

“The Propanc Executive team are delighted with advancements made in the past financial year,” said Mr. James Nathanielsz, Propanc’s Chief Executive Officer. “The Company is poised to capitalize on the foundation set in the next financial year with the advancement of PRP to a Phase 1b FIH study in up to 50 advanced cancer patients with solid tumors such as pancreatic, ovarian and refractory prostate cancers. Recent clinical advancements observed by companies such as Revolution Medicines and Erasca through KRAS inhibitors for pancreatic cancer are groundbreaking and tremendously exciting, but there is more work to be done to eliminate recurrence and metastasis in patients suffering from this killer disease. PRP is a potential breakthrough therapy that modulates the tumor micro-environment by targeting the EMT (epithelial-mesenchymal transition) process, which drives metastasis, invasion and recurrence from CSCs (cancer stem cells) which often lie dormant, post treatment, causing the cancer to return and spread. By eliminating this threat, not only can PRP improve survival, but is also non-toxic to healthy cells, meaning that patients could have a better quality of life, as well as enhance more durable response rates in combination with other treatments such as chemotherapy, checkpoint inhibitors, or KRAS inhibitors. We look forward to executing our scientific and clinical research activities in the 2026-2027 financial year.”

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.

More information: www.propanc.com

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

Company:
Propanc Biopharma, Inc.
James Nathanielsz

+61-3-9882-0780
info@propanc.com

Investor Contact:

irteam@propanc.com

Clinical Research Activity for PRP		Timeline
CTA		April 2025 – September 2026
Phase Ib Clinical Study Protocol
Investigator’s Brochure
CTA Compilation		October 2026 – November 2026
CTA Submission		November 2026
CTA Approval		February 2027
CTA Review		January 2027 – February 2027
Contract Research Organization and Contracts		February 2027 – March 2027
Analytical Laboratory Selection and Contracts
Trial Site Selection and Contracts
Preparation of Logistics		February 2027 – March 2027
Trial Site Initiation Visits
First Patient/First Visit		April 2027

PROPANC BIOPHARMA, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS
		June 30, 2026				June 30, 2025
ASSETS
CURRENT ASSETS:
Cash		$	832,006			$	12,088
GST tax receivable			13,694				5,302
Prepaid expenses – current portion			7,661,967				8,334,046
Other current assets			34,923				1,380
TOTAL CURRENT ASSETS			8,542,590				8,352,816
Deferred offering costs			–				291,773
Prepaid expenses – long-term portion			4,190,543				10,925,835
Security deposit – related party			2,074				1,971
Operating lease right-of-use assets, net – related party			40,790				59,413
Property and equipment, net			3,915				–
TOTAL ASSETS		$	12,779,912			$	19,631,808
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable		$	1,131,429			$	1,249,596
Accrued expenses and other payables			855,350				1,486,550
Accrued interest			128,318				190,795
Loans payable			–				65,280
Loans payable – related parties, net of discount			460,809				415,329
Notes payable, net of discount			–				543,312
Convertible notes, net of discounts and including put premiums			–				537,921
Operating lease liability – related party, current portion			24,489				17,664
Embedded conversion option liabilities			–				403,892
Employee benefit liability			754,038				667,901
TOTAL CURRENT LIABILITIES			3,354,433				5,578,240
NON-CURRENT LIABILITIES:
Loan payable – long-term – related party, net of discount			–				105,627
Operating lease liability – long-term portion – related party			23,818				41,749
TOTAL NON-CURRENT LIABILITIES			23,818				147,376
TOTAL LIABILITIES		$	3,378,251			$	5,725,616
Commitments and Contingencies (See Note 9)
STOCKHOLDERS’ EQUITY:
Preferred stock, 1,500,005 shares authorized, $0.01 par value:
Series A preferred stock, $0.01 par value; 500,000 shares previously authorized; 0 shares issued and outstanding as of June 30, 2026 and 2025		$	–			$	–
Series B preferred stock, $0.01 par value; 5 shares authorized; 1 share issued and outstanding as of June 30, 2026 and 2025			–				–
Series C preferred stock, $0.01 par value, $10,000 stated value; 5 shares authorized; 9,900 shares designated and authorized, 200 (liquidation value of $2,000,000) shares and none issued and outstanding at June 30, 2026 and 2025, respectively			2				–
Common stock, $0.001 par value; 10,000,000,000 shares authorized; 3,310,827 and 464,471 shares issued and outstanding as of June 30, 2026 and 2025, respectively			3,310				464
Common stock issuable (487,939 and 310 shares as of June 30, 2026 and 2025, respectively)			487				–
Additional paid-in capital			152,752,314				138,254,808
Accumulated other comprehensive income			1,176,255				1,318,917
Accumulated deficit			(144,484,230	)			(125,621,520	)
Treasury stock ($0.001 share)			(46,477	)			(46,477	)
TOTAL STOCKHOLDERS’ EQUITY			9,401,661				13,906,192
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY		$	12,779,912			$	19,631,808

PROPANC BIOPHARMA, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
		For the years ended June 30,
		2026				2025
REVENUE
Revenue		$	–			$	–
OPERATING EXPENSES
Administration expenses			670,607				108,950
Compensation and related taxes			2,275,937				23,296,390
Professional and consulting expenses			14,572,616				33,622,510
Occupancy expenses – related party			40,932				26,560
Research and development			625,477				223,721
TOTAL OPERATING EXPENSES			18,185,569				57,278,131
LOSS FROM OPERATIONS			(18,185,569	)			(57,278,131	)
OTHER INCOME (EXPENSE)
Interest expense			(430,539	)			(563,757	)
Interest income			161				9
Derivative expense			–				(333,596	)
Change in fair value of derivative liabilities			13,709				212,450
Change in fair value of warrant liability			(99,695	)			–
Other expense			(6,000	)			–
Settlement expense			(320,000	)			–
Gain (loss) on extinguishment of debt, net			133,071				(871,032	)
Foreign currency transaction gain (loss)			32,152				(89,243	)
TOTAL OTHER INCOME (EXPENSE), NET			(677,141	)			(1,645,169	)
LOSS BEFORE TAXES			(18,862,710	)			(58,923,300	)
Tax benefit			–				–
NET LOSS		$	(18,862,710	)		$	(58,923,300	)
Deemed Dividend			(932,246	)			–
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS		$	(19,794,956	)		$	(58,923,300	)
BASIC AND DILUTED NET LOSS PER SHARE		$	(17.62	)		$	(371.22	)
BASIC AND DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING			1,123,709				158,727
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS		$	(19,794,956	)		$	(58,923,300	)
OTHER COMPREHENSIVE INCOME (LOSS)
Unrealized foreign currency translation gain (loss)			(142,662	)			49,336
TOTAL OTHER COMPREHENSIVE INCOME (LOSS)			(142,662	)			49,336
TOTAL COMPREHENSIVE LOSS		$	(19,937,618	)		$	(58,873,964	)

Vancouver, BC, Sept. 29, 2026 (GLOBE NEWSWIRE) — Humanoid Global Holdings Corp. (“Humanoid Global” or the “Company”) (CSE:ROBO, FWB:0XM1, OTCQB:RBOHF), a publicly traded investment issuer focused on building and accelerating a portfolio of pioneering companies in humanoid robotics and embodied artificial intelligence (“AI”), is pleased to highlight recent corporate and commercial developments announced by MBody AI Ltd. (“MBody AI”) (Nasdaq: MBAI), a portfolio company in which Humanoid Global holds a minority equity interest.

MBody AI announced that, on August 26, 2026, Check-Cap Ltd. completed its business combination with MBody AI Corp. Under the transaction, MBody AI Corp. became a wholly owned subsidiary of Check-Cap, and Check-Cap shareholders approved a corporate name change to MBody AI Ltd. The combined company continues to trade on Nasdaq under the symbol MBAI.

MBody AI further announced the closing, on August 27, 2026, of an underwritten public offering of 1,538,462 ordinary shares at a public offering price of $6.50 per share, for gross proceeds of approximately 10.0 million before underwriting discounts, commissions and offering expenses. The underwriter was granted a 30-day option to purchase up to an additional 230,769 ordinary shares at the public offering price, less applicable underwriting discounts and commissions.

Separately, on September 9, 2026, MBody AI announced that it had completed a proof-of-concept deployment of autonomous robotic systems at Mohegan Sun in Uncasville, Connecticut. According to MBody AI, the systems continued operating following the conclusion of the pilot and transitioned to a paid commercial agreement with Mohegan Sun.

MBody AI has stated that its robots operated across Mohegan Sun’s gaming floor and conference centre, including full day and evening shifts, and performed repetitive and time-sensitive tasks. MBody AI further stated that the deployment is managed through its “MBody AI Orchestrator,” a hardware-agnostic platform intended to coordinate robot fleets across sites and use cases.

According to MBody AI, Mohegan Sun has indicated its intention to expand the deployment under a multi-year subscription arrangement later in 2026. Any such expansion remains subject to negotiation and execution of definitive agreements between MBody AI and Mohegan Sun.

“The completion of MBody AI’s business combination and financing represents an important transition for the company as it advances its embodied-AI and autonomous-robotics strategy as a Nasdaq-listed issuer,” said Sunny Ray, Chief Executive Officer of Humanoid Global. “We believe the paid commercial deployment at Mohegan Sun provides an additional operating example of MBody AI’s approach to converting robotics deployments into recurring commercial relationships. Humanoid Global continues to monitor and support the progress of its portfolio companies while maintaining disciplined minority-investment positions.”

Humanoid Global does not control or operate MBody AI and is not a party to MBody AI’s arrangement with Mohegan Sun, its business combination with Check-Cap, or its public offering. The Company holds securities of MBody AI and, subject to applicable securities laws, may acquire or dispose of such securities from time to time.

Humanoid Global invests in companies supporting the commercial adoption of robotics, automation and embodied AI across the global economy.

-##-

About Humanoid Global Holdings Corp.

Humanoid Global Holdings Corp.  (CSE:ROBO, FWB:0XM1, OTCQB:RBOHF) (“Humanoid Global” or the “Company”) is a publicly traded investment issuer building a portfolio of pioneering companies in the growing humanoid robotics and embodied AI sector, investing in and accelerating their growth. It serves as a global investment platform providing liquidity and access to an actively managed portfolio spanning the value chain of this emerging ecosystem, including advanced software, hardware, and enabling technologies. Led by a team with a proven track record of scaling transformative technologies globally, the Company takes a long-term, partnership-oriented approach. It provides capital and strategic consultation on go-to-market strategies, regulatory pathways, and transaction advisory, while facilitating introductions to customers, suppliers, and strategic partners.

Learn more:
https://www.humanoidglobal.ai/

For further information, please contact:

Sunny Ray
Chief Executive Officer

finance@humanoidglobal.ai
info@humanoidglobal.ai
(604) 602-0001

CSE:ROBO
OTCQB:RBOHF
FWB:0XM1

ON BEHALF OF MANAGEMENT

Sunny Ray
Chief Executive Officer

Cautionary Note Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements regarding: the anticipated expansion, timing, scope, terms and commercial benefits of MBody AI’s deployment at Mohegan Sun; the potential negotiation and execution of a multi-year subscription agreement or other expansion arrangement between MBody AI and Mohegan Sun; the continuation, renewal or extension of MBody AI’s commercial engagement at Mohegan Sun; MBody AI’s ability to convert proof-of-concept or pilot deployments into commercial operations; MBody AI’s ability to deploy, operate, scale and commercialize its autonomous robotics systems and fleet-orchestration platform; the anticipated use of proceeds from MBody AI’s public offering; and the Company’s expectations regarding its investment in MBody AI.

Forward-looking information is based on assumptions that MBody AI’s commercial engagement with Mohegan Sun will continue substantially as anticipated; the parties will be able to negotiate and execute any proposed expansion agreement on acceptable terms; MBody AI will have sufficient capital, personnel, technology, equipment, commercial partners and other resources to support its current and future deployments; MBody AI will be able to maintain its Nasdaq listing and comply with applicable regulatory requirements; and market conditions and demand for autonomous robotics and embodied-AI solutions will remain supportive. These assumptions may prove to be incorrect. The Company holds a minority equity interest in MBody AI and therefore has a financial interest in MBody AI’s success and the market price of its securities; readers should consider this interest when evaluating the forward-looking information contained herein. Humanoid Global does not control or operate MBody AI, is not a party to MBody AI’s arrangement with Mohegan Sun, business combination or public offering, and has no control over the negotiation, execution, terms or performance of any MBody AI commercial agreement.

Forward-looking information is subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied, including: the risk that no expansion agreement is entered into with Mohegan Sun, or that any such agreement is entered into on different terms or at a different time than anticipated; the risk that MBody AI’s existing commercial engagement at Mohegan Sun is modified, suspended, terminated or not renewed; the risk that MBody AI’s autonomous robotic systems or orchestration platform may not perform as expected or achieve commercial acceptance; risks relating to technology performance, systems integration, safety, cybersecurity, data security, maintenance, operational reliability and customer acceptance; risks that MBody AI may require additional capital or may not be able to obtain financing on acceptable terms or at all; risks associated with MBody AI’s ability to maintain compliance with Nasdaq continued-listing requirements and other applicable regulatory requirements; customer-concentration, commercialization and competition risks; changes in applicable laws, regulations or government policies; general business, economic, financial and market conditions; and risks related to the Company’s reliance on portfolio companies in which it holds minority interests and over which it does not have control.

Additional risks are described in the Company’s public filings available under its profile on SEDAR+ at www.sedarplus.ca. Forward-looking information speaks only as of the date of this news release, and the Company undertakes no obligation to update or revise it except as required by applicable law. Readers are cautioned not to place undue reliance on forward-looking information.

Certain information in this news release regarding MBody AI, its business combination with Check-Cap, its public offering, its autonomous robotics systems, the MBody AI Orchestrator and its deployment at Mohegan Sun has been derived from MBody AI’s public announcements and other publicly available sources. Humanoid Global has not independently verified this information. The Company is not the operating company and is not a party to the business combination, public offering, commercial arrangement, customer relationship or other operating activities described in this news release.

SAN DIEGO, Sept. 29, 2026 (GLOBE NEWSWIRE) — Lite Strategy, Inc. (Nasdaq: LITS) (“Lite Strategy” or the “Company”), the first U.S. public company to adopt Litecoin (LTC) as its primary treasury reserve asset announced financial results for the fiscal year ended June 30, 2026.

Fiscal year 2026 was the Company’s first fiscal year operating under the LTC treasury strategy that commenced in August 2025. The Company deployed $100.0 million to acquire over 900,000 LTC, built the foundation of an active digital asset treasury by establishing institutional custody and professional asset management, and launched active digital asset treasury operations. Each of these elements is directed at increasing the LTC backing behind every share of LITS common stock.

Fiscal Year 2026 Operational Highlights

• Closed a $100.0 million private placement in July 2025 and deployed the gross proceeds into LTC, establishing LTC as the Company’s primary treasury reserve asset and the largest public company holder of LTC; the Company held 832,716 LTC as of June 30, 2026, representing over 1% of LTC currently mined;
• Led a $1.0 million strategic investment in LitVM, the first zero-knowledge Layer-2 platform bringing smart contract capability to the Litecoin network;
• Shifted from accumulation to active capital markets operations in the second fiscal quarter, launching a covered call options program against LTC holdings and commencing repurchases of LITS common stock under a $25.0 million share repurchase program approved in October 2025;
• Initiated pre-clinical activities for voruciclib in non-oncology indications, retaining two drug candidates for potential out-licensing or sale opportunities and future sources of non-dilutive capital.

“Fiscal 2026 was the year we built the base for a Litecoin-centered treasury program,” said Jay File, CEO & CFO of Lite Strategy. “We deployed $100 million into Litecoin with institutional custody alongside professional management through GSR Strategies, then launched a covered call program ahead of schedule that generates recurring proceeds. Those proceeds, together with the strategic utilization of our Litecoin balance, are designed to allow us the ability to monetize our discount to NAV and put more Litecoin behind every share via our ongoing buyback program. As we move into our first full year of DAT operations, we anticipate that our focus will be on accretive buybacks, expanded yield opportunities, lower operational costs and cash burn, while continuing to evaluate strategic opportunities to expand Litecoin’s utility and growth of the Litecoin ecosystem.”

Fiscal Year 2026 and Recent Financial Highlights

• Repurchased approximately 4.4 and 6.4 million LITS shares, or 12% and 17% of shares outstanding, from the commencement of the buyback program through June 30, 2026 and September 22, 2026, respectively; halving the discount to net asset value (NAV) from the low 40% range into the low 20% range;
• Premium proceeds generated from covered call program of approximately $930,000 from program initiation through September 22, 2026.

Cash and Liquidity
At June 30, 2026, Lite Strategy held $5.7 million in cash and cash equivalents and $34.9 million in unrestricted and collateralized digital assets, with total assets of $42.7 million and no debt. The Company had 30,407,268 shares outstanding as of September 22, 2026. Complete financial statements are available in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (Commission).

Litecoin Ecosystem Outlook
On March 17, 2026, the Commission issued the Digital Asset Interpretation, identifying LTC as a digital commodity rather than a security, with the Commodity Futures Trading Commission (CFTC) joining to confirm it will continue to regulate LTC on that basis. The Commission expanded on that guidance on August 18, 2026, proposing Regulation Crypto Assets, a tailored offering framework now open for public comment. For corporate treasuries and asset managers evaluating LTC exposure, this offers meaningful assurance that was not available a year ago.

While the CLARITY Act did not advance in the U.S. Senate, the guidance already issued by the Commission and the CFTC gives the Company a clear basis to continue executing its LTC-focused strategy under the regulatory framework and guidance currently available. The Company intends to remain focused on executing our disciplined treasury management strategy focused on long-term stockholder value creation within those requirements while monitoring legislative and regulatory developments.

“Together, these efforts introduce a comprehensive, tailored securities offering regime intended to address long-standing barriers to responsible capital formation and innovation within domestic crypto asset markets, while preserving the investor protections at the core of federal securities laws,” said Charlie Lee, Lite Strategy Board Member and creator of Litecoin.

Business Update and Strategic Focus
Looking ahead, management’s primary objective is to grow LTC holdings per share through the active management of the Company’s treasury.

We believe the opportunity underlying this strategy is significant. Institutional and corporate capital allocated to digital asset treasuries has grown rapidly over the past two years, yet that capital remains heavily concentrated in Bitcoin, leaving Litecoin as one of the longest-operating, most liquid and lowest-cost payment networks in digital assets, with a fixed, disclosed supply and a 15-year operating history; comparatively underrepresented relative to its scale, security and track record. Management believes that gap represents a durable opportunity: as regulatory clarity accelerates institutional adoption of LTC and as the network’s utility expands, demand for LTC should broaden beyond its traditional base as a payments asset. For Lite Strategy, that dynamic reinforces the core investment thesis.

As the first U.S. public company to adopt LTC as its primary treasury reserve asset and its largest public company holder, Lite Strategy offers investors a liquid, regulated, publicly traded vehicle for direct exposure to LTC’s growth, without the custody, security and operational complexity of holding the asset directly. Management believes this positioning allows the Company to compound that opportunity for stockholders as institutional awareness of, and demand for, LTC increases.

Beyond treasury management, Lite Strategy intends to invest in the growth of the Litecoin ecosystem itself. LitVM has the capacity to extend Litecoin from a payment network to a programmable one, and Lite Strategy is its lead institutional investor. Applications built on the platform broaden Litecoin’s utility, including the LTC held in the Company’s treasury. By enabling smart contracts, decentralized finance, stablecoin issuance and tokenized assets on Litecoin for the first time, LitVM should have the opportunity to meaningfully expand the network’s addressable use cases beyond payments alone, creating new sources of transaction activity and developer engagement.

Following the Digital Asset Interpretation, and with a full fiscal year of operating record with our Litecoin-centered treasury program and no outstanding debt, management intends to expand direct engagement with banking partners, analysts and allocators. Alongside sustained education in the case for LTC as an institutional asset, a broader institutional understanding of LTC supports the value of the Company’s own holdings. Management remains focused on bridging institutional capital to the Litecoin ecosystem. We believe Lite Strategy is well positioned to capture an attractive share of this opportunity as one of the only pure-play, publicly traded vehicles offering direct exposure to LTC’s growth.

About Lite Strategy
Lite Strategy Inc. (Nasdaq LITS) is a San Diego-based digital asset treasury company that holds LTC as a primary reserve asset and pursues capital markets strategies designed to generate income from those holdings while retaining long-term exposure. Formerly MEI Pharma, Inc., the Company adopted its Litecoin treasury strategy in 2025 to diversify reserves, enhance capital efficiency and align with emerging financial technologies. Lite Strategy also retains a portfolio of pharmaceutical assets that it is managing for out-licensing or sale. More information is available at litestrategy.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding LTC and its potential performance, the Company’s Litecoin treasury strategy, the share repurchase program, out-licensing or sale of pharmaceutical assets and the sufficiency of the Company’s capital resources. These statements are subject to risks and uncertainties, including volatility in the price of LTC, the regulatory treatment of digital assets, the Company’s ability to maintain compliance with Nasdaq listing standards, potential dilution from outstanding warrants and options and the other risks described in the Company’s filings with the Securities and Exchange Commission. Actual results may differ materially. The Company undertakes no obligation to update any forward-looking statement except as required by law.

Contacts:

Investor Relations:
Alliance Advisors IR
Adele Carey
SVP, Investor Relations
investor@litestrategy.com

Public Relations:
Impact3
Casey Wilson
Director of Public Relations
media@litestrategy.com

New agreements bring the total value of contracts signed over the past seven months to more than $3.45 billion

PITTSBURGH, Sept. 29, 2026 (GLOBE NEWSWIRE) — Axe Compute Inc. (NASDAQ: AGPU) today announced that it has received more than $184 million in customer prepayments and signed over $266 million in new AI infrastructure contracts since reporting second-quarter results on August 17, 2026.

The prepayments, drawn from both newly signed agreements and existing contracts, represent capital committed ahead of delivery, underscoring surging demand and momentum as Axe Compute turns contracted commitments into revenue.

The $266 million in new contracts is incremental to previously disclosed agreements, bringing the total value of contracts signed in the past seven months to more than $3.45 billion. The new agreements have terms of up to 60 months and include Grace Blackwell 300-class hardware, accompanied by CPU nodes to run orchestration, Kubernetes, Slurm and other control functions, as well as high speed storage and dedicated network connectivity to support lightning fast inferencing and mission critical applications. These GB300 clusters support clients building AI cloud platforms and running inference, fine-tuning, and other production AI workloads.

“Customers are committing to the dedicated AI infrastructure they want with Axe Compute, and our team is executing to deliver exactly what they need to grow their businesses,” said Christopher Miglino, Chief Executive Officer of Axe Compute. “Demand is clear. Our focus is on delivering the infrastructure, performance, and operational accountability our customers are counting on.”

Axe Compute designs, deploys, and operates dedicated AI infrastructure for enterprises building and running production AI workloads. Headquartered in Pittsburgh, the company delivers purpose-built GPU capacity backed by predictable performance, transparent costs, and end-to-end operational accountability.

About Axe Compute Inc.
Axe Compute Inc. (NASDAQ: AGPU) is a neocloud AI infrastructure platform built on a fundamental premise: AI innovation should not be constrained by hardware choice or availability. The company provides enterprises and AI innovators with flexibility across hardware, geography, and deployment models. Axe Compute provides the design, deployment, ownership, and operation of large-scale, dedicated AI infrastructure worldwide, supported by enterprise-grade SLAs and operational expertise. Axe Compute is headquartered in Pittsburgh, Pennsylvania. For more information, visit axecompute.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding the commencement, timing, deployment and activation of contracted customer projects; deployment and operational capabilities; customer demand; contracted customer projects; capacity roadmap; hardware availability; and the company’s ability to design, deploy, own and operate dedicated AI infrastructure at scale. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied by such statements. Axe Compute undertakes no obligation to update or revise forward-looking statements except as required by applicable law.

Media and Investor Relations Contact

Erin McMahon, CMO and Head of Investor Relations
ir@axecompute.com

Experienced public company legal executive will lead nVent’s global legal, compliance and corporate governance functions

LONDON, Sept. 29, 2026 (GLOBE NEWSWIRE) — nVent Electric plc (nVent), a global leader in electrical connection and protection solutions, today announced the appointment of Courtney Nelson Wills as Executive Vice President, General Counsel and Secretary, effective October 12. Wills will report directly to nVent Chair and CEO Beth Wozniak and will lead nVent’s global legal organization, including the compliance, corporate governance and corporate secretary functions. She will be based out of nVent’s management offices in St. Louis Park, MN.

“Courtney is a strategic public company general counsel with decades of legal, business and governance experience across global organizations,” said Beth Wozniak, nVent Chair and CEO. “Her passion for business, technology and people makes her a great fit for nVent, and she will provide strong leadership as we continue to execute our growth strategy.”

Nelson Wills joins nVent with more than 25 years of experience spanning global commercial operations, public-company governance, M&A, intellectual property and regulatory and compliance matters. Most recently, she served as Senior Vice President, General Counsel and Corporate Secretary of MiniMed Group, Inc., a multibillion-dollar spin-off from Medtronic which completed its IPO in early 2026.

“I’m honored to join nVent and excited about the opportunities ahead,” said Courtney Nelson Wills. “nVent is a company with a strong track record, exciting growth strategy and a great culture focused on people and performance. I look forward to working with the leadership team and employees around the world to support the company’s continued success.”

Nelson Wills earned a Juris Doctor from the University of Minnesota Law School and a Bachelor of Science degree in Chemical Engineering from the University of Minnesota.

About nVent 

nVent is a leading global provider of electrical connection and protection solutions. We believe our inventive electrical solutions enable safer systems and ensure a more secure world. We design, manufacture, market, install and service high-performance products and solutions that connect and protect some of the world’s most sensitive equipment, buildings and critical processes. We offer a comprehensive range of systems protection and electrical connections solutions across industry-leading brands that are recognized globally for quality, reliability and innovation. Our principal office is in London and our management office in the United States is in Minneapolis. Our robust portfolio of leading electrical product brands dates back more than 100 years and includes nVent CADDY, ERICO, HOFFMAN, ILSCO, SCHROFF and TRACHTE. Learn more at www.nVent.com.

nVent, CADDY, ERICO, HOFFMAN, ILSCO, SCHROFF and TRACHTE are trademarks owned or licensed by nVent Services GmbH or its affiliates.

Investor Contact
Tony Riter
Vice President, Investor Relations
nVent
763.204.7750
Tony.Riter@nVent.com

Media Contact
Kevin H. King
Vice President, Global Communications
nVent
763.291.0526
Kevin.King@nVent.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8e2d88a6-bf57-4269-bb58-626c561bcdf7

Five-year task order provides comprehensive systems support for integrated capabilities that strengthen U.S. border security, protect the American people, and support national economic prosperity

RESTON, Va., Sept. 29, 2026 (GLOBE NEWSWIRE) — Science Applications International Corp. (NASDAQ: SAIC) announced today it has been awarded a $742 million recompete task order to provide full-scale support for U.S. Customs and Border Protection (CBP) systems that are essential to securing our borders and assessing security risk from travelers and cargo entering our country. This award further cements SAIC’s critical role in helping CBP drive an integrated border security mission.

As the prime contractor, SAIC will provide comprehensive systems support, including software development, operations, maintenance, upgrades, and enhancements. The work will help CBP rapidly respond to evolving technologies, threats, and mission requirements in support of Department of Homeland Security (DHS) initiatives to strengthen U.S. border security, protect the American people, and support national economic prosperity. The task order was issued under Alliant 2 and has a period of performance from September 15, 2026, through September 14, 2031.

“For more than 25 years, our teams have partnered with CBP to further its mission, tackle its operational challenges, and meet the needs of its highly skilled workforce,” said Prabu Natarajan, SAIC Chief Financial Officer and Interim Leader of the Civilian Business Group. “We do not just build tools for operators; we develop and enhance integrated capabilities for the CBP. By applying our ‘Operator First’ mission-driven approach, and outstanding performance, we will help CBP achieve faster, safer and more effective mission outcomes.”

SAIC also recently won a five-year, $199 million recompete task order for the agency’s Integrated Traveler Initiatives (ITI) 2.1 program. Through ITI 2.1, SAIC will continue supporting technologies that enable secure and efficient processing at ports of entry and inspection checkpoints.

About SAIC 
SAIC® is a premier mission integrator focused on advancing the power of technology and innovation to serve and protect our world. Our robust portfolio of offerings across the defense, space, intelligence, and civilian markets includes secure high-end solutions in mission IT, enterprise IT, engineering services, and professional services. We rapidly integrate emerging technologies into mission operations that modernize and enable critical national imperatives.

We are approximately 23,000 strong; driven by mission, united by purpose, and inspired by opportunities. Headquartered in Reston, Virginia, SAIC has annual revenues of approximately $7.3 billion. For more information, visit saic.com. For ongoing news, please visit our newsroom.

Media Contact: 
Caralyn Duke
publicrelations@saic.com

Forward-Looking Statements 
Forward-Looking Statements Certain statements in this release contain or are based on “forward-looking” information within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “guidance,” and similar words or phrases. Forward-looking statements in this release may include, among others, estimates of future revenues, operating income, earnings, earnings per share, charges, total contract value, backlog, outstanding shares and cash flows, as well as statements about future dividends, share repurchases and other capital deployment plans. Such statements are not guarantees of future performance and involve risk, uncertainties and assumptions, and actual results may differ materially from the guidance and other forward-looking statements made in this release as a result of various factors. Risks, uncertainties and assumptions that could cause or contribute to these material differences include those discussed in the “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Legal Proceedings” sections of our Annual Report on Form 10-K, as updated in any subsequent Quarterly Reports on Form 10-Q and other filings with the SEC, which may be viewed or obtained through the Investor Relations section of our website at saic.com or on the SEC’s website at sec.gov. Due to such risks, uncertainties and assumptions you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. SAIC expressly disclaims any duty to update any forward-looking statement provided in this release to reflect subsequent events, actual results or changes in SAIC’s expectations. SAIC also disclaims any duty to comment upon or correct information that may be contained in reports published by investment analysts or others. 

Through it’s subsidiary ReachOut, Frequency adds zero-dilution vendor financing facility through Capchase Pay designed to bring contract cash forward, and creating capacity to support millions in new growth.

Chicago, IL, Sept. 29, 2026 (GLOBE NEWSWIRE) — Frequency Holdings Inc. (OTC: FRQN), a technology-focused holding company building and acquiring assets across cybersecurity, managed intelligence, digital infrastructure and media, today announced that its wholly owned subsidiary, ReachOut Digital Intelligence, has secured $5 million in zero-dilution working capital capacity through Capchase Pay. The facility is eligible to increase to $10 million after 120 days.

Frequency Holdings FRQN – Rick Jordan CEO – Announces $5M Financing Facility

The new structure allows ReachOut to receive the value of multi-year customer agreements upfront while customers make payments over time through Capchase. For ReachOut, this fundamentally changes the cash-flow dynamics of growth. Instead of waiting three or more years to collect cash under long-term agreements, the Company can bring that cash forward on day 1 and redeploy it into sales, product development, operations, and continued expansion. The $5 million capacity gives ReachOut financial infrastructure designed to support millions of dollars in new multi-year contracts without relying on equity issuance to fund ordinary growth.

“Last week we told the market that we were putting the capital structure where we believe it belongs and getting ready to hit the gas. This is one of the mechanisms that lets us do that,” said Rick Jordan, CEO of Frequency Holdings. “This changes the financial infrastructure underneath ReachOut. Instead of waiting three or five years to collect the cash from a customer agreement, we can bring that cash forward and immediately put it back to work growing the business.”

TURNING CONTRACTED GROWTH INTO WORKING CAPITAL

ReachOut has increasingly structured its cybersecurity, IT and managed intelligence offerings as multi-year licensed protection agreements. Those agreements can include software licensing, cybersecurity platforms, equipment, implementation, ongoing management and other technology required to operate and protect the customer environment.

Historically, rapid growth under a recurring-payment model can create a cost inversion. The provider incurs a significant portion of the cost to acquire, deploy and support a new customer early in the relationship while collecting the corresponding contract value over several years.

This capital structure substantially changes that equation.

“We are creating a very different growth cycle,” Jordan said. “Sell. Fund. Deploy. Put the capital back to work. Repeat. We can give customers the normal recurring payments while front-loading the operating capital necessary to scale much faster on our side.”

FROM CAPITAL STRUCTURE TO GROWTH PLATFORM

The announcement follows Frequency’s September 22 reduction of its authorized common shares from 5.4 billion to 250 million and authorized preferred shares from 1.1 billion to 250 million.

At the time, Frequency said the restructuring was intended to create a capital structure appropriate for the Company’s next stage of revenue growth, strategic acquisitions and managed intelligence commercialization.

The new capital relationship represents an early example of that strategy moving from structure into operating capability.

“This is exactly why cleaning up the capital structure mattered,” Jordan said. “Growth requires capital, but capital does not always need to come from issuing shares. We want multiple ways to finance growth, and this gives ReachOut a powerful one tied directly to the business we are already selling.”

The initial $5 million capacity is eligible to increase to $10 million after 120 days, providing additional room as ReachOut expands its customer base and increases the volume of multi-year agreements.

Frequency expects the financing capability to support ReachOut’s broader expansion across cybersecurity-first IT, licensed protection and managed intelligence as the Company continues building repeatable offerings designed for small and mid-sized businesses.

About Frequency Holdings Inc.

Frequency Holdings Inc. (OTC: FRQN) is a technology-focused holding company building and acquiring assets across cybersecurity, managed intelligence, digital infrastructure and media.

Through its wholly owned subsidiary ReachOut Digital Intelligence, the Company provides cybersecurity-first IT and AI solutions to small and mid-sized businesses. Frequency is developing managed intelligence offerings designed to automate business processes with AI while maintaining strong cybersecurity, compliance and governance controls.

The Company’s broader strategy combines recurring operating revenue, strategic acquisitions, AI commercialization and media distribution to build a portfolio of scalable technology assets.

Forward-Looking Statements

This press release contains forward-looking statements concerning Frequency Holdings Inc.’s growth strategy, future customer agreements, use and expansion of financing capacity, working capital, revenue growth, managed intelligence commercialization and other future business activities. Forward-looking statements are based on management’s current expectations and assumptions and involve risks and uncertainties that may cause actual results to differ materially from those expressed or implied.

The Company cannot guarantee the amount or timing of future customer contracts, utilization or expansion of financing capacity, revenue growth, acquisitions, commercialization milestones or other strategic initiatives discussed herein. Frequency Holdings Inc. undertakes no obligation to publicly update or revise forward-looking statements except as required by applicable law.

Press Inquiries

Public Relations
pr [at] frequencyhold.com
3122888008
https://frequencyhold.com/

Veteran Process, Refining and Fischer-Tropsch Engineer Joins Leadership Team as American EcoFuels Advances GTL and CTL Fuel Development Program

SOUTHLAKE, Texas, Sept. 29, 2026 (GLOBE NEWSWIRE) — American EcoFuels Inc. (OTC: AEFI) (“American EcoFuels” or the “Company”), a developer of advanced synthetic fuel technologies, today announced the appointment of Sasa Dzaferovic, Ph.D., as Chief Processing Officer (“CPO”), adding more than two decades of process, chemical, safety and environmental engineering experience to the Company’s technical leadership team.

The appointment of Dr. Dzaferovic follows American EcoFuels’ continued expansion of its engineering organization as the Company progresses its proprietary Gas-to-Liquids (“GTL”) and Coal-to-Liquids (“CTL”) development program. Working with the Company’s engineering leadership, Dr. Dzaferovic will focus specifically on the process side of American EcoFuels’ technology, helping translate the Company’s underlying chemistry and intellectual property into an integrated process capable of producing consistent liquid hydrocarbon products.

The Company intends for its development program to ultimately produce aviation fuel in quantities sufficient for comprehensive testing and advancement through the applicable ASTM qualification pathway, with the longer-term objective of supplying fuels for commercial aviation, aircraft and engine manufacturers, and appropriate U.S. military applications, subject in each case to successful testing, qualification, applicable specifications and customer acceptance.

American EcoFuels also intends to pursue potential offtake relationships and agreements as its engineering, testing and qualification programs progress.

“Dr. Dzaferovic brings an exceptional combination of process engineering, refinery, gas-processing and Fischer-Tropsch experience to American EcoFuels at exactly the time we are expanding our engineering and fuel-development efforts,” said Brent Nelson, Executive Chairman of American EcoFuels. “Sasa understands not only the science of converting syngas into liquid hydrocarbons, but also the engineering required to integrate these processes into real operating systems. As we move deeper into engineering, testing and ultimately production of our aviation fuels, we believe his experience will be an important addition to our technical leadership.”

Direct Fischer-Tropsch, Refining and Hydroprocessing Experience

Dr. Dzaferovic brings more than 22 years of oil and gas industry experience, including extensive work in refining, natural-gas processing, natural-gas liquids extraction, acid-gas compression and injection, sulfur recovery, gas sweetening, petrochemical manufacturing and renewable-energy processes. His background also includes eight years of scientific research and university lecturing.

Of particular importance to American EcoFuels, Dr. Dzaferovic has direct experience with GTL Fischer-Tropsch processing, including a refinery configuration and optimization study involving the conversion of carbon monoxide (CO) and hydrogen (H₂) into liquid hydrocarbons including diesel, jet fuel and naphtha.

As Chief Processing Officer, Dr. Dzaferovic is expected to provide senior technical leadership for the Company’s proprietary GTL and CTL process development, including process modeling, optimization, system integration, hydrocarbon conversion, product upgrading and the engineering necessary to advance American EcoFuels’ technology toward increasingly sophisticated test and commercial systems.

His experience is particularly relevant to the Company’s objective of converting carbon-containing feedstocks into synthesis gas and subsequently rebuilding those molecular constituents into higher-value liquid hydrocarbons. Dr. Dzaferovic’s refinery experience includes work involving atmospheric distillation, fluid catalytic cracking, heavy-oil fractionation, naphtha/jet and gas-oil hydrotreaters, delayed cokers and carbon-capture technology.

His professional experience also includes hydroprocessing reactor design on a major synthetic-crude upgrader expansion and extensive work involving refinery process modeling, optimization, hydrocracking, hydrotreating, sulfur recovery and hydrogenation and catalyst-regeneration processes.

Building the American EcoFuels Processing Platform

American EcoFuels believes Dr. Dzaferovic’s appointment represents another important step in assembling the engineering organization required to advance the Company’s proprietary fuel technologies. His responsibilities as CPO are expected to include oversight and coordination of key processing disciplines involved in taking feedstock through the Company’s conversion pathway—from feedstock preparation and synthesis-gas generation through Fischer-Tropsch conversion, hydrocarbon upgrading, separation and final product optimization.

Dr. Dzaferovic has extensive experience with process simulation and modeling platforms including AspenTech HYSYS, BR&E ProMax and Symmetry (VMG), as well as steady-state and dynamic modeling, dynamic safety analysis, process optimization, operational support, gas processing and sulfur recovery. His gas-processing experience includes pre-FEED, FEED and detailed engineering for large sour- and sweet-gas processing facilities, process modeling, compression, dehydration, amine sweetening, refrigeration, liquids recovery and fractionation, acid-gas injection and CO₂ transmission.

“The Fischer-Tropsch process gives us the ability to take carbon monoxide and hydrogen and catalytically construct liquid hydrocarbons, but producing a finished aviation fuel requires considerably more than a single reaction,” Nelson continued. “The entire process—from syngas quality and catalyst operating conditions through separation, hydroprocessing, upgrading and final fuel properties—has to work together. Sasa’s background is exceptionally well aligned with that challenge.”

Academic and International Engineering Background

Dr. Dzaferovic holds a Doctorate in Mathematics, a Master of Applied Science in Chemical Engineering, and a Bachelor of Applied Science in Chemical Engineering from the University of Sarajevo.

His career has included major energy and infrastructure projects in Canada and internationally. He has worked on process design, simulation, safety systems and thermodynamic modeling and has served in senior consulting and engineering leadership roles. His experience includes establishing a Process Engineering division and dedicated Centre of Knowledge at Gemini Corporation and working on refinery, upgrader and LNG systems at Fluor Daniel.

His experience also extends to renewable-energy projects, energy-decarbonization and net-zero strategy work, as well as LNG liquefaction and regasification systems involving refrigeration cycles, mixed refrigerants and cryogenic heat exchange.

About American EcoFuels Inc.

American EcoFuels Inc. (OTC: AEFI) is developing advanced synthetic fuel technologies intended to convert natural gas and coal-derived feedstocks into high-performance liquid hydrocarbons, including Sustainable Aviation Fuel, synthetic paraffinic kerosene, modified clean diesel and related engineered fuels.

Through its GTL and CTL technology platforms, proprietary catalysts and expanding intellectual property portfolio, American EcoFuels is working toward fuels designed to provide the high energy density required by aviation, transportation, defense and industrial applications while utilizing existing engines and fuel infrastructure where applicable and following required testing and certification.

The Company’s development strategy encompasses technology engineering, intellectual property development, test-plant operation, fuel testing and certification, strategic partnerships, potential commercial production projects and prospective technology licensing.

American EcoFuels – From Discovering Energy to Engineering It

Forward-Looking Statements

This news release contains statements regarding future events, expectations, plans, objectives and potential outcomes that are forward-looking in nature and are subject to significant risks and uncertainties. These statements include, among others, statements concerning the anticipated contributions of the Company’s Chief Processing Officer and engineering personnel; the development, testing, qualification, financing and commercialization of the Company’s technologies; GTL and CTL processes; Fischer-Tropsch processing; production of aviation and other fuels; ASTM qualification and specification activities; regulatory, military or customer acceptance; expansion of the Company’s intellectual property portfolio; potential strategic partnerships, offtake arrangements, production facilities and licensing opportunities; and the Company’s ability to execute its business plan.

Forward-looking statements are based on management’s current expectations, estimates, assumptions and projections and involve risks and uncertainties that could cause actual results, developments or events to differ materially from those anticipated. There can be no assurance that the Company’s technologies will achieve expected performance, that its fuels will successfully complete applicable testing or qualification processes or obtain required certifications, that ASTM specifications or other regulatory or customer requirements will be satisfied, that airlines, aircraft or engine manufacturers, the U.S. Department of Defense or any branch of the U.S. military will approve, purchase or use the Company’s fuels, that anticipated offtake agreements will be executed, or that the Company will successfully finance, scale or commercialize its technologies. Additional risks include engineering and scale-up risks, intellectual property challenges, financing requirements, regulatory developments, feedstock availability and pricing, competition, market acceptance, environmental requirements and general economic conditions.

Readers should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and American EcoFuels undertakes no obligation to publicly update or revise such statements except as required by applicable law.

Company Contact:

American EcoFuels Inc.
OTC: AEFI
Phone: 877.233.4485 ext. 730
Email: info@americanecofuelsinc.com
Website: www.americanecofuelsinc.com

Viome founder and CEO brings a consumer-focused vision for bringing regenerative therapies to more people and advancing proactive health

FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative medicine company, today announced that Naveen Jain, founder and Chief Executive Officer of Viome Life Sciences Inc. (“Viome”), will join its Board of Directors.

Jain founded InfoSpace, Intelius, TalentWise and Moon Express and is the founder and CEO of Viome, which applies AI and molecular data to personalized health and nutrition. He joins Celularity’s Board with a consumer-focused perspective on healthcare’s shift from treating illness to helping people take a more proactive role in their health. He will bring that perspective to the challenge of bringing promising regenerative therapies to more consumers.

“Naveen has devoted considerable energy to the pursuit of longer, healthier lives, and shares our belief in the significant potential of regenerative longevity,” said Robert J. Hariri, M.D., Ph.D., Chairman and Chief Executive Officer of Celularity. “He has a track record of pursuing ambitious ideas and building businesses around emerging technologies. That perspective will be valuable as we work to expand the commercial reach of Celularity’s products and capabilities and explore the broader opportunities at the intersection of regenerative medicine and longevity.”

“Healthcare is shifting from treating illness after symptoms appear to helping people take a more proactive role in their health. Regenerative medicine has the potential to be an important part of that shift. I’m joining Celularity’s Board to help translate that potential into real-world impact, bringing a consumer perspective, commercial discipline and partnerships to the work of bringing these therapies to more people,” said Naveen Jain.

“Naveen brings a perspective that is crucial to what we are building around the boardroom,” said fellow Board member, Philip A. Barach. “We have made meaningful progress strengthening Celularity’s capital structure and operating profile. The opportunity now is to pair that discipline with an ambitious commercial vision for the assets the Company has already created.”

Mr. Jain joins the Company’s newly constituted Board consisting of Dr. Hariri, Peter H. Diamandis, M.D., and Mr. Barach, who recently joined the Board as part of Celularity’s broader recapitalization and strategic repositioning. Celularity expects to announce a fifth director shortly. Mr. Jain’s appointment to the Board will become effective following completion of the applicable Rule 14f-1 information statement process.

About Naveen Jain

From personalized health to space exploration, Naveen Jain has built companies around questions with world-scale stakes. He is the founder and CEO of Viome Life Sciences, where AI and molecular data are applied to personalized health and nutrition. He previously founded InfoSpace, Intelius and TalentWise, and also founded Moon Express. Across technology, health and space, Jain has pursued a singular entrepreneurial vision: turn emerging technologies into new ways to address humanity’s biggest challenges.

About Celularity

Celularity Inc. (Nasdaq: CELU) is a longevity-focused regenerative and cellular medicine company developing and manufacturing allogeneic and autologous cell therapies derived from the postpartum placenta. Celularity draws on the placenta’s unique biology, immunologic properties and scalable availability to develop therapeutic solutions targeting fundamental mechanisms of aging and age-related disease. Its cellular therapy portfolio includes cenplacel-L, its investigational placenta-derived allogeneic cell therapy, and other investigational cellular therapies. Celularity is headquartered in Florham Park, New Jersey, where it operates a purpose-built cGMP research and manufacturing facility supporting the development and manufacture of cellular therapies, advanced biomaterials and other longevity and wellness-focused products.

For more information, please visit www.celularity.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding Mr. Jain’s anticipated appointment to and contributions as a member of the Company’s Board of Directors; the Company’s strategy to expand the commercial reach of its products and capabilities; the potential for regenerative medicine and the Company’s technologies to address aging and age-related disease and contribute to more proactive approaches to health; the Company’s ability to translate its technologies into commercial opportunities, expand access to its products and develop strategic partnerships; and the expected appointment of an additional director.

These forward-looking statements are based on management’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including risks relating to regulatory requirements and approvals, clinical development, manufacturing, commercialization and market acceptance, the Company’s ability to execute its business strategy and obtain sufficient financing, and the other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Celularity undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.

Investor and Media Contact:

info@celularity.com